Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY 3.25
(0.31%)
CNY 3.25
(0.31%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 387.96 Million CNY | 182.63% |
| 2022 | -960.81 Million CNY | -133.52% |
| 2021 | 1.33 Billion CNY | -18.76% |
| 2020 | 1.79 Billion CNY | -29.12% |
| 2019 | 1.37 Billion CNY | -4.2% |
| 2018 | 2.98 Billion CNY | 45.4% |
| 2017 | 2.01 Billion CNY | 75.3% |
| 2016 | 1.06 Billion CNY | 135.93% |
| 2015 | 449.82 Million CNY | 35.97% |
| 2014 | 343.9 Million CNY | 25.78% |
| 2013 | 273.97 Million CNY | 32.61% |
| 2012 | 194.39 Million CNY | 43.42% |
| 2011 | 142.42 Million CNY | 42.6% |
| 2010 | 101.95 Million CNY | 39.23% |
| 2009 | 73.89 Million CNY | 49.56% |
| 2008 | 48.53 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 65.54 Million CNY | 13.05% |
| 2024 Q1 | 66.13 Million CNY | 255.58% |
| 2024 Q2 | 71.52 Million CNY | -13.5% |
| 2023 Q3 | 336.6 Million CNY | 807.38% |
| 2023 Q4 | -313.88 Million CNY | -193.25% |
| 2023 FY | - CNY | 182.63% |
| 2023 Q1 | 169.09 Million CNY | 110.67% |
| 2023 Q2 | 37.09 Million CNY | -78.06% |
| 2022 Q3 | 316.84 Million CNY | 117.39% |
| 2022 Q4 | -1.58 Billion CNY | -600.3% |
| 2022 FY | - CNY | -133.52% |
| 2022 Q1 | 295.8 Million CNY | 169.27% |
| 2022 Q2 | 145.74 Million CNY | -50.73% |
| 2021 FY | - CNY | -18.76% |
| 2021 Q2 | 361.61 Million CNY | -20.31% |
| 2021 Q3 | 374.98 Million CNY | 3.7% |
| 2021 Q4 | 109.85 Million CNY | -70.7% |
| 2021 Q1 | 453.78 Million CNY | 92.25% |
| 2020 Q4 | 236.04 Million CNY | -53.92% |
| 2020 Q3 | 512.25 Million CNY | 33.21% |
| 2020 FY | - CNY | -29.12% |
| 2020 Q1 | 571.21 Million CNY | 13.0% |
| 2020 Q2 | 384.55 Million CNY | -32.68% |
| 2019 Q2 | 685.95 Million CNY | 7.96% |
| 2019 Q3 | 710.76 Million CNY | 3.62% |
| 2019 FY | - CNY | -4.2% |
| 2019 Q1 | 635.39 Million CNY | 10.17% |
| 2019 Q4 | 505.48 Million CNY | -28.88% |
| 2018 Q3 | 809.61 Million CNY | 11.31% |
| 2018 FY | - CNY | 45.4% |
| 2018 Q4 | 576.71 Million CNY | -28.77% |
| 2018 Q2 | 727.35 Million CNY | 23.84% |
| 2018 Q1 | 587.33 Million CNY | -30.43% |
| 2017 FY | - CNY | 75.3% |
| 2017 Q3 | 473.88 Million CNY | -19.32% |
| 2017 Q4 | 844.27 Million CNY | 78.16% |
| 2017 Q2 | 587.38 Million CNY | 271.88% |
| 2017 Q1 | 157.95 Million CNY | -56.0% |
| 2016 FY | - CNY | 135.93% |
| 2016 Q2 | 213.06 Million CNY | 24.51% |
| 2016 Q3 | 325.69 Million CNY | 52.86% |
| 2016 Q4 | 359 Million CNY | 10.23% |
| 2016 Q1 | 171.12 Million CNY | 19.58% |
| 2015 Q2 | 93.66 Million CNY | -1.78% |
| 2015 Q3 | 107.59 Million CNY | 14.88% |
| 2015 Q4 | 143.1 Million CNY | 33.01% |
| 2015 FY | - CNY | 35.97% |
| 2015 Q1 | 95.35 Million CNY | 3.11% |
| 2014 Q3 | 92.99 Million CNY | 26.24% |
| 2014 Q2 | 73.66 Million CNY | 1.25% |
| 2014 Q1 | 72.75 Million CNY | -13.02% |
| 2014 FY | - CNY | 25.78% |
| 2014 Q4 | 92.48 Million CNY | -0.55% |
| 2013 Q2 | 58.1 Million CNY | 0.5% |
| 2013 FY | - CNY | 32.61% |
| 2013 Q4 | 83.64 Million CNY | 14.18% |
| 2013 Q3 | 73.26 Million CNY | 26.09% |
| 2013 Q1 | 57.81 Million CNY | -9.94% |
| 2012 Q4 | 64.19 Million CNY | 23.03% |
| 2012 Q3 | 52.18 Million CNY | 33.38% |
| 2012 Q2 | 39.12 Million CNY | -2.49% |
| 2012 Q1 | 40.11 Million CNY | -9.29% |
| 2012 FY | - CNY | 43.42% |
| 2011 FY | - CNY | 42.6% |
| 2011 Q3 | 32.31 Million CNY | 5.77% |
| 2011 Q2 | 30.55 Million CNY | 14.99% |
| 2011 Q1 | 26.57 Million CNY | -3.07% |
| 2011 Q4 | 44.22 Million CNY | 36.85% |
| 2010 Q2 | 27.68 Million CNY | 45.13% |
| 2010 Q4 | 27.41 Million CNY | 3.5% |
| 2010 FY | - CNY | 39.23% |
| 2010 Q1 | 19.07 Million CNY | 0.0% |
| 2010 Q3 | 26.48 Million CNY | -4.32% |
| 2009 FY | - CNY | 49.56% |
| 2008 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 4.03 Billion CNY | 90.378% |
| Shenzhen Glory Medical Co.,Ltd. | -24.58 Million CNY | 1677.873% |